CD34 and AL amyloidosis: Furthermore, we show that eltrombopag promotes megakaryopoiesis in CD34+ cells isolated from myeloma patients and healthy controls via activation of Akt signaling pathways, providing preclinical proof-of-principle to support the design of future clinical trials examining eltrombopag for the treatment of thrombocytopenia in patients with relapsed multiple myeloma.